Thursday, Encorium Group Inc. (ENCO) re-appointed Kai Lindevall as Chief Executive Officer. Lindevall had previously served as Executive Chairman and President of Europe and Asia from July 2009 until present, Chief Executive Officer of the Company from February 2008 until September 2008 and as President, Europe and Asian Operations from November 2006 until February 2008.
In addition, the Board appointed Shahab Fatheazam, a current director of the Company, as Chairman of the Board of Directors. Fatheazam most recently was Managing Director and head of the U.S. healthcare practice of GCA Savvian, a leading international investment banking advisory firm. Fatheazam joined GCA Savvian in 2004 from Vector Securities, a premier healthcare specialty firm, where he was a partner.
Encorium Group Inc. designs and manages clinical trials for pharmaceutical, biotechnology, and medical device industries primarily in Europe. The company's clinical research and development services supporting Phase I through Phase IV clinical trials include data management, data entry, clinical/statistical reports, and writing manuscripts.
For comments and feedback: editorial@rttnews.com